Showing results (41-50 of 79) with videos related to
Sort By:
Pageof 8
Diagnostics (Basel, Switzerland)|October 28, 2023
More Than a Decade of GeneXpert<sup>®</sup><i>Mycobacterium tuberculosis</i>/Rifampicin (Ultra) Testing in South Africa: Laboratory Insights from Twenty-Three Million TestsManuel Pedro da Silva, Naseem Cassim, Silence Ndlovu, et al.Clinical Breast Cancer|October 5, 2015
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast CancerJohn W Smith, Svetislava Vukelja, Anthony D Hoffman, et al.Diagnostics (Basel, Switzerland)|January 8, 2023
Rapid Evaluation of the Xpert<sup>®</sup> Xpress CoV-2 <i>plus</i> and Xpert<sup>®</sup> Xpress CoV-2/Flu/RSV <i>plus</i> TestsLara Dominique Noble, Lesley Erica Scott, Riffat Munir, et al.General Hospital Psychiatry|February 24, 2022
A virtual, pilot randomized trial of a brief intervention to prevent suicide in an integrated healthcare settingNatalie B Riblet, Lauren Kenneally, Susan Stevens, et al.Peerj|June 29, 2019
Linked within-host and between-host models and data for infectious diseases: a systematic reviewLauren M Childs, Fadoua El Moustaid, Zachary Gajewski, et al.Journal for Immunotherapy of Cancer|May 24, 2014
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy ProgramRoxanne Payne, Lyn Glenn, Helena Hoen, et al.Breast Cancer Research and Treatment|May 22, 2009
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancerJohn W Smith, Kristi J McIntyre, Patrick V Acevedo, et al.Diagnostics (Basel, Switzerland)|February 25, 2022
Monitored Implementation of COVID-19 Rapid Antigen Screening at Taxi Ranks in Johannesburg, South AfricaMohammed Majam, Vanessa Msolomba, François Venter, et al.Journal of the National Cancer Institute|February 19, 2004
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancerJohn Nemunaitis, Daniel Sterman, David Jablons, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003
Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinomaJohn W Smith II, Robert A Kurt, Angelo G Baher, et al.Pageof 8